Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Prostate specific antigen: its proper diagnostic use]

L Boccon-Gibod1

  • 1Clinique Urologique, Hôpital Bichat, Paris.

Presse Medicale (Paris, France : 1983)
|January 8, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malformations, genetic abnormalities, and Wilms tumor.

Pediatric blood & cancer·2013
Same author

[Prostate cancer, androgenic suppression and associated conditions. Practical refinement by a panel of multidisciplinary experts for patient integral management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2012
Same author

[New perspectives in prostate cancer management].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2010
Same author

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Annals of oncology : official journal of the European Society for Medical Oncology·2010
Same author

[First line indications for hormonal therapy in prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2010
Same author

[AFU 2008 congress: Summary of the main communications about prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2009

Prostate specific antigen (PSA) is a tissue marker, not a tumor marker. PSA testing aids early prostate cancer diagnosis in men under 70 with a life expectancy over 10-15 years, but is not routinely recommended for older men.

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Context:

  • Prostate specific antigen (PSA) is a clinically significant biomarker.
  • Understanding PSA's role in prostate cancer diagnosis is crucial.
  • Current guidelines for PSA testing vary, especially by age.

Purpose:

  • To clarify the diagnostic utility of PSA testing.
  • To define appropriate indications for PSA assay and subsequent investigations.
  • To differentiate PSA's role as a tissue marker versus a tumor marker.

Summary:

  • Prostate specific antigen (PSA) functions as a tissue marker, not a tumor marker.
  • PSA testing is valuable for early prostate cancer diagnosis when clinical suspicion is high.
  • In men under 70 with a life expectancy >10-15 years, elevated PSA warrants further investigation (ultrasonography, biopsy).

Related Experiment Videos

  • PSA testing is generally not indicated for men over 70 unless prostatic disease is suspected.

    • Impact:

    • Optimizes the use of PSA testing for early prostate cancer detection.
    • Reduces unnecessary testing and potential patient anxiety in older populations.
    • Facilitates timely diagnosis and treatment for eligible patients, improving outcomes.